

Peer reviewed Publikationen aus der Neurologischen Klinik und Poliklinik mit Forschungsgruppen 2019 (Originalarbeiten, Reviews, Letters)

1. Achtnichts L, Chan A, Czaplinski A, **Derfuss T**, Du Pasquier R, Findling O, Gobbi C, Hoepner R, Kamber N, Kamm CP, **Kuhle J**, Lalive P, Lutterotti A, Martin R, Müller S, **Papadopoulou A**, Pot C, Salmen A, Schippling S, Zecca C, In cooperation with the Scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. *Clinical and Translational Neuroscience*. 2019 3 (1), 2514183X18822073 (IF n/a)
2. Albrecht DS, Mainero C., Ichijo E., Ward, N., **Granziera C.**, Zürcher N. R., Akeju O., Bonnier G., Price J., Hooker JM, Napadow V., Loggia ML, Hadjikhani N. In-vivo Imaging of Neuroinflammation in Migraine with Aura – a [11C]PBR28 PET/MR Study. *Neurology*, 2019 Apr 23; 92(17):e2038-e2050. (IF 8.689)
3. **Altermatt A, Gaetano L, Magon S**, Bauer L, Feurer R, Gnahn H, Hartmann J, Seifert CL, Poppert H, **Wuerfel J, Radue EW, Kappos L**, Sprenger T Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study. *Neuroimage*. 2019 Apr 1;189:727-733 (IF 5.812)
4. Babiloni C, Del Percio C, Lizio R, Noce G, Lopez S, Soricelli A, Ferri R, ... **Fuhr P, Gschwandtner U**,... & De Pandis MF. Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. *Neurobiol Aging*. 2019 Jan;73:9-20 (IF 4.398)
5. Babiloni C, Del Percio C, Pascarelli M T, Lizio R, Noce G, Lopez S, Rizzo M, ... **Fuhr P, Gschwandtner U**, & Bonanni L. Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. *Neurobiology of aging*, 2019 May;77:112-127 (IF 4.398)
6. Barkhof F, **Kappos L**, Wolinsky JS, Li DKB., Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL. Onset of clinical and MRI efficacy of Ocrelizumab in relapsing Multiple Sclerosis. *Neurology*. 2019 Nov 5;93(19):e1778-e1786. (IF 8.689)
7. Bendfeldt K, Taschler B, **Gaetano L**, Madoerin P, Kuster P, Mueller-Lenke N, **Amann M**, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, **Kappos L**, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, **Sprenger T, Radue EW, Wuerfel J**, Nichols TE MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. *Brain Imaging Behav*. Oct. 2019 13:1361–1374 (IF 3.418)

8. Bjornevik K, Munger KL, Cortese M, **Barro C**, Healy BC, Niebuhr DW, Scher AI, **Kuhle J***, Ascherio A*. *Equal contribution. Serum neurofilament light chain as a presymptomatic biomarker in multiple sclerosis. *JAMA Neurol*, 2019 Sep 13. doi: 10.1001/jamaneurol.2019.3238 (IF 12.321)
9. **Bischof A**, Jäger V, Hadden R, Luqmani R, **Pröbstel AK**, Merkel P, Suppiah, Craven A, Collins M, Daikeler T. Peripheral Neuropathy in ANCA-Associated Vasculitides: Insights from the DCVAS Study. *Neurology: Neuroimmunology & Neuroinflammation*. 2019. 6(6): pii:e615. PMID: 31540965 (IF 7.353)
10. Browne R, Jakimovski D, **Kuhle J**, Weinstock-Guttman B, Zivadinov R, Ramanathan M. High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus? *J Clin Lipidol*, 13:654-663, 2019. (IF 3.581)
11. Canto E, **Barro C**, Zhao C, Caillier SJ, **Michalak Z**, Bove R, Tomic D, Santaniello A, Häring DA, Hollenbach J, Henry RG, Cree BCA, **Kappos L**, **Leppert D**, Hauser SL, Benkert P, Oksenberg JR*, **Kuhle J***. *Equal contribution. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. *JAMA Neurol*. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2137. (IF 12.321)
12. Burggraaff J, Dorn J, **D'Souza M**, Morrison C, Kamm CP, Kontschieder P, Tewarie P, Steinheimer S, Sellen A, Dahlke F, **Kappos L**, Uitdehaag B. Video-Based Pairwise Comparison: Enabling the Development of Automated Rating of Motor Dysfunction in Multiple Sclerosis. *Arch Phys Med Rehabil*. 2020 Feb;101(2):234-241. Epub 2019 Aug 30 (IF 2.697)
13. Castets P, Rion N, Théodore M, Falchetta D, Lin S, Reischl M, Wild F, Guérard L, Eickhorst C, Brockhoff M, Guridi M, Ibebunjo C, Cruz J, **Sinnreich M**, Rudolf R, Glass DJ, Rüegg MA. mTORC1 and PKB/Akt control the muscle response to denervation by regulating autophagy and HDAC4. *Nat Commun*. 2019 Jul 18;10(1):3187. (IF 11.8)
14. **Chaturvedi M**, Bogaarts JG, **Kozak VV**, **Hatz F**, **Gschwandtner U**, **Meyer A**, **Fuhr P**, Roth V. Phase lag index and spectral power as QEEG features for identification of patients with mild cognitive impairment in Parkinson's disease. *Clin Neurophysiol* 2019;130(10):1937-1944. (IF: 3.675)
15. Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; **International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders**. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. *Lancet Neurol*. 2019 Feb;18(2):185-197. (IF 28.755)
16. Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree Bac, Sheffield JK, Minton N, Raghupathi K, Huang V, **Kappos L**; RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. *Lancet Neurol*. 2019 Nov;18(11):1021-1033. (IF 28.755)

17. Comi G, **Kappos L**, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; Sunbeam Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. *Lancet Neurol*. 2019 Nov;18(11):1009-1020. (IF 28.755)
18. Conen D, Rodondi N, Müller A, Beer JH, Ammann P, Moschovitis G, Auricchio A, Hayoz D, Kobza R, Shah D, Novak J, Schläpfer J, Di Valentino M, Aeschbacher S, Blum S, Meyre P, Sticherling C, **Bonati LH**, Ehret G, Moutzouri E, Fischer U, Monsch AU, Stippich C, **Wuerfel J**, **Sinnecker T**, Coslovsky M, Schwenkglens M, Kühne M, Osswald S; Swiss-AF Study Investigators. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. *J Am Coll Cardiol*. 2019; 73(9):989-999. (IF 18.639)
19. Cuello JP, Ginés M, **Kuhle J**, Domínguez M, Ros AL, Delgado FR, Higuera Y, Rivera AM, Briceño HG, Larroca S, Ruiz J, **Michalak Z**, **Barro C**, Lafuente R, Heras SM, Velasco J, Tejeda-Velarde A, Domínguez-Mozo M, Muriel A, de Andrés C, Villar LM. Neurofilament light chain levels in pregnant multiple sclerosis patients: A prospective cohort study. *Eur J Neurol* 2019, 26:1200-1204 (IF 4.387)
20. **D'Souza M**, Heikkilä A, **Lorscheider J**, **Haller V**, **Kravalis K**, Gysin S, Fuertes NAC, **Fricker E**, Lam E, Higgins P, Tomic D, **Papadopoulou A**, **Kappos L**. Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials. *Mult Scler*. 2019 May 7:1352458519845108. doi: 10.1177/1352458519845108 (IF 5.649)
21. De Sitter A, Visser M, Brouwer I, Cover KS, Van Schijndel RA, Eijgelaar RS, Müller DMJ, Ropele S, **Kappos L**, Rovira Á, Filippi M, Enzinger C, Frederiksen J, Ciccarelli O, Guttman CRG, Wattjes MP, Witte MG, De Witt Hamer PC, Barkhof F, Vrenken H; MAGNIMS Study Group and Alzheimer's Disease Neuroimaging Initiative. Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods. *Eur Radiol*. 2020 Feb;30(2):1062-1074. Epub 2019 Nov 5 (IF 3.962)
22. **Décard BF**, Gohritz A Intraneurale Ganglienzysten – Bildgebung ist der Schlüssel! *Klin Neurophysiol* 2019; 50(04): 235-236, (IF 0.158)
23. **Derfuss T**, Sellebjerg F, Dönnies P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. *J Neuroimmunol*. 2019 Jan 15;326:19-27. (IF 2.8)
24. **Diebold M**, **Altersberger V**, **Décard BF**, **Kappos L**, **Derfuss T**, **Lorscheider J**. PML with dimethyl fumarate - No convincing case against natalizumab. *Mult Scler*. 2019 Oct;25(12):1687-1688. (IF 5.649)
25. **Diebold M**, **Altersberger V**, **Décard BF**, **Kappos L**, **Derfuss T**, **Lorscheider J**. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate

treatment without severe lymphopenia or immunosenescence. *Mult Scler.* 2019 Oct;25(12):1682-1685. (IF 5.649)

26. **Diebold M, Fischer-Barnicol B, Tsagkas C, Kuhle J, Kappos L, Derfuss T, Décard BF.** Hepatitis E Virus infections in multiple sclerosis patients on oral disease modifying treatment. *Neurol Neuroimmunol Neuroinflamm.* 2019 Jul 11;6(5). pii: e594. (IF 7.353)
27. **Diebold M, Müller S, Derfuss T, Décard BF.** A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions. *Mult Scler Relat Disord.* 2019 Mar 9;31:38-40. (IF 3.199)
28. **Diebold M, Derfuss T.** The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis. *Ther Adv Neurol Disord.* Mar 2019, eCollection 2019. (IF 4.750)
29. **Disanto G, Prosperetti C, Gobbi C, Barro C, Michalak Z, Cassina T, Kuhle J, Casso G, Agazzi P.** Serum neurofilament light chain as a prognostic marker in post-anoxic encephalopathy. *Epilepsy Behav.* 2019 Dec;101(Pt B):106432. doi: 10.1016/j.yebeh.2019.07.033. Epub 2019 Jul 30 (IF 2.061)
30. Elliott C, Wolinsky J, Hauser S, **Kappos L**, Barkhof F, Bernasconi C, Wei Wei, Belachew S, Arnold D. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions *Mult Scler.* 2019 Dec;25(14):1915-1925. (IF 5.649)
31. Evers KS, Huhn EA, Fouzas S, **Barro C, Kuhle J, Fisch U**, Bernasconi L, Lapaire O, Wellmann S. Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort – a prospective study. *BMC Pregnancy Childbirth.* 2019 Nov 5;19(1):403. doi: 10.1186/s12884-019-2570-6 (IF 2.331)
32. Fartaria MJ, Sati P., Todea A., **Radue EW, Rahmanzadeh R.**, O'Brien K., Reich, DS, Bach Cuadra M., Kober T., **Granziera C.** Automated detection and segmentation of multiple sclerosis lesions using ultra-high-field MP2RAGE. *Investigative Radiology.* 2019 Jun;54(6):356-364. (IF 6.091)
33. Fartaria M.J., Kober T., **Granziera C***, Bach-Cuadra M>(*equal contribution). Longitudinal analysis of white matter and cortical lesions in multiple sclerosis. *Neuroimage Clinical.* 2019;23:101938. doi: 10.1016/j.nicl.2019.101938. (IF 3.943)
34. **Fladt J, Meier N, Thilemann S, Polymeris AA, Traenka C, Seiffge DJ, Sutter R, Peters N, Gensicke H,** Fluckiger B, De Hoogh K, Kunzli N, Bringolf-Isler B, **Bonati LH, Engelter ST, Lyrer PA and De Marchis GM** Reasons for Prehospital Delay in Acute Ischemic Stroke *J Am Heart Assoc.* 2019;8:e013101. (IF 4.660)
35. **Fladt J, Hofmann L, Coslovsky M, Imhof A, Seiffge DJ, Polymeris A, Thilemann S, Traenka C, Sutter R,** Schaer B, Kaufmann BA, **Peters N, Bonati LH, Engelter ST, Lyrer PA and De Marchis GM** Fast-track versus long-term hospitalizations for patients with non-disabling acute ischaemic stroke *Eur J Neurol* 2019;26:51-57. (IF 4.387)

36. Fox M, Meyer-Gerspach AC, **Wendebourg MJ**, Gruber M, Heinrich H, Sauter M, Woelnerhanssen B, Koeberle D, Juengling F. Effect of cocoa on the brain and gut in healthy subjects: a randomised controlled trial. *Br J Nutr.* 2019 Mar;121(6):654-661. (IF 3.319)
37. Galli E, Hartmann FJ, Schreiner B, Ingelfinger F, Arvaniti E, **Diebold M**, Mrdjen D, van der Meer F, Krieg C, Al Nimer F, **Sanderson N**, Stadelmann C, Khademi M, Piehl F, Claassen M, **Derfuss T**, Olsson T, Becher B. GM-CSF and CXCR4 Define a T Helper Cell Signature in Multiple Sclerosis. *Nat Med* 2019 Aug;25(8):1290-1300 (IF 30.6)
38. Galovic M, Stauber AJ, Leisi N, Krammer W, Brugger F, Vehoff J, Balcerak P, Muller A, Muller M, Rosenfeld J, **Polymeris A**, **Thilemann S**, **De Marchis GM**, Niemann T, Leifke M, **Lyrer P**, Saladin P, Kahles T, Nedeltchev K, Sarikaya H, Jung S, Fischer U, Manno C, Cereda CW, Sander JW, Tettenborn B, Weder BJ, Stoeckli SJ, Arnold M and Kagi G Development and Validation of a Prognostic Model of Swallowing Recovery and Enteral Tube Feeding After Ischemic Stroke *JAMA Neurol.* 2019 May 1;76(5):561-570 (IF 12.321)
39. Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, **Kappos L**, Pozzilli C, Montalban X, De Stefano N; and The Magnims Study Group Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. *Neurology.* 2019 Jan 22;92(4):180-192 (IF 8.689)
40. Grzonka P, Tisljar K, **Rüegg S**, Marsch S, Sutter R. What to exclude when brain death is suspected. *J Crit Care* 2019; 53(10):212-217. (IF 2.783)
41. Ham AS, Chojnowska K, Tintignac LA, Lin S, Schmidt A, Ham DJ, **Sinnreich M**, Rüegg MA. mTORC1 signalling is not essential for the maintenance of muscle mass and function in adult sedentary mice. *J Cachexia Sarcopenia Muscle.* 2019 Nov 7. doi: 10.1002/jcsm.12505. (IF 12.5)
42. **Hardmeier, M.**, Jacques, F., Albrecht, P., Bousleiman, H., Schindler, C., Leocani, L., & **Fuhr, P.** Multicentre assessment of motor and sensory evoked potentials in multiple sclerosis: reliability and implications for clinical trials. *Mult Scler J Exp Transl Clin.* 2019 May 1;5(2):2055217319844796. doi: 10.1177/2055217319844796 (IF n/a)
43. **Hatz F**, **Meyer A**, Roesch A, Taub E, **Gschwandtner U**, **Fuhr P.** Quantitative EEG and Verbal Fluency in DBS Patients: Comparison of Stimulator-On and -Off Conditions. *Front Neurol.* 2019 Jan 9;9:1152. doi: 10.3389/fneur.2018.01152 (IF 3.508)
44. Jakimovski D, **Kuhle J**, Ramanathan M, **Barro C**, Tomic D, Hagemeyer J, Kropshofer H, Bergsland N, **Leppert D**, Dwyer MG, **Michalak Z**, Benedict RHB, Weinstock-Guttman B, Zivadinov R. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. *Ann Clin Transl Neurol* 2019, 6:1757-1770 (IF 4.656)

45. Jakimovski D, Zivadinov R, Ramanathan M, Hagemeyer J, Weinstock-Guttman B, Tomic D, Kropshofer H, Fuchs TA, **Barro C, Leppert D, Yaldizli Ö, Kuhle J**, Benedict RH. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. *Mult Scler*, 2019, Oct 15:1352458519881428. doi: 10.1177/1352458519881428 (IF 5.649)
46. Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, **Lindberg RLP**, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, **Derfuss T**, Sellebjerg F, Dönnies P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. *J Neuroimmunol*. 2019 Jan 15;326:19-27. (IF 2.8)
47. Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofri M, Lugaresi A, Ozakbas S, **Kappos L, Kuhle J**, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2019, 90:458-468 (IF 8.327)
48. Kaufmann M, Puhon MA, **Kuhle J, Yaldizli Ö**, Magnusson T, Kamm CP, **Calabrese P**, von Wyl V. A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis. *Front Neurol*. 2019 Sep 4;10:953. (IF: 3.552)
49. Kellinghaus C, Rossetti AO, Trinkka E, Lang N, May TW, Unterberger I, **Rüegg S**, Sutter R, Strzelczyk A, Tilz C, Uzelac Z, Rosenow F. Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE). *Ann Neurol* 2019; 85(3): 421-432. (IF 9.496)
50. Kellinghaus C, Rossetti AO, Trinkka E, Lang N, May TW, Unterberger I, **Rüegg S**, Sutter R, Strzelczyk A, Tilz C, Uzelac Z, Rosenow F. Sustained Network for treatment of Status Epilepticus (SENSE) – A multicenter prospective observational registry. *Epilepsy Behav* 2019; Nov 4:106553. doi: 10.1016/j.yebeh.2019.106553. [Epub ahead of print]. (IF 2.378).
51. **Kronlage C**, Healy DG. Mystery Case: Bilateral alopecia as clue to diagnosis of Gomez-Lopez-Hernandez syndrome in a 38-year-old man. *Neurology* 2019, 93(9), 408–410.(IF 8.689)
52. **Kuhle J***, Kropshofer H*, Haering DA, Kundu U, Meinert R, **Barro C**, Dahlke F, Tomic D, **Leppert D, Kappos L**. *Equal contribution. Blood neurofilament light

chain as a biomarker of MS disease activity and treatment response. *Neurology*, 92:e1007-e1015, 2019. (IF 8.689)

53. **Kuhle J**, Plavina T, **Barro C**, **Disanto G**, Sangurdekar D, Singh CM, de Moor C, Engle B, Kieseier BC, Fisher E, **Kappos L**, Rudick RA, Goyal, J. Neurofilament Light Levels Are Associated With Long-term Outcomes in Multiple Sclerosis. *Mult Scler*, 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613 2019.(IF 5.649)
54. Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, **Kuhle J**, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercaemmen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. *Mult Scler*, 2019 May 8:1352458519845844. doi: 10.1177/1352458519845844 (IF 5.649)
55. **Lorscheider J**, **Kuhle J**, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, **Kappos L**, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. *Eur J Neurol*, 26:363-370, 2019. (IF 4.387)
56. Luescher T, Mueller J, Isenschmid C, Kalt J, Rasiah R, Tondorf T, Gamp M, Becker C, **Sutter R**, Tisljar K, Schuetz P, Marsch S, Hunziker S. Neuron-specific enolase (NSE) improves clinical risk scores for prediction of neurological outcome and death in cardiac arrest patients: results from a prospective trial. *Resuscitation*. 2019; 142: 50-60. (IF 4.572)
57. **Magon S**, **Pfister A**, **Gaetano L**, **Lüthi M**, **Papadopoulou A**, **Kappos L**, **Sprenger T**. Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study. *Brain Imaging Behav* 2019 Jul 27: 1-7. (IF 3.418)
58. Malekzadeh A, Leurs C, Van Wieringen W, Steenwijk MD, Schoonheim MM, **Amann M**, **Naegelin Y**, **Kuhle J**, **Kappos L**, Killestein J, Teunissen CE. Plasma proteome in multiple sclerosis disease progression. *Annal Clin Transl Neurol* 2019, 6:1582-1594 (IF 4.649)
59. Manno C, **Disanto G**, Bianco G, Nannoni S, Heldner M, Jung S, Arnold M, Kaesmacher J, Muller M, **Thilemann S**, **Gensicke H**, Carrera E, Fischer U, Kahles T, Luft A, Nedeltchev K, Staedler C, Cianfoni A, Kagi G, **Bonati LH**, Michel P And Cereda Cw Outcome of endovascular therapy in stroke with large vessel occlusion and mild symptoms *Neurology* 2019;93:e1618-e26. (IF 8.689)
60. Mayer L, **Kappos L**, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, Koendgen H, Li C, Napieralski J, Zheng H, Wolinsky JS. Ocrelizumab infusion

experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. *Mult Scler Relat Disord*. 2019 Jan 28;30:236-243. (IF 2.725)

61. Mehta D*, Miller C*, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, **Kappos L**, Liu S, Matta A, Phillips JT, Robertson D, Von Hehn CA, Yang L, Fox RJ (* Co-First Authors) Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. *Neurology* 2019 Apr 9;92(15):e1724-e1738. (IF 8.689)
62. **Meira M**, Sievers C, Hoffmann F, **Bodmer H**, **Derfuss T**, **Kuhle J**, Haghikia A, **Kappos L**, **Lindberg RL**. PARP-1 deregulation in multiple sclerosis. *Mult Scler J Exp Transl Clin*. 2019 Dec 16;5(4):2055217319894604. eCollection 2019 Oct-Dec (IF n/a)
63. Merkies, I.S.J., van Schaik, I. N., Leger, J. M., Bril, V., van Geloven, N., Hartung, H. P, Lewis, R. A., Sobue, G., Lawo, J. P., Durn, B. L., Cornblath, D. R, De Bleecker, J. L., Sommer, C., Robberecht, W, Saarela, M., Kamienowski, J., Stelmasiak, Z., Tackenberg, B., Mielke, O., Prima Trial Investigators, the **Path Study Group**, Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. *J Peripher Nerv Syst*, 2019. 24(1): p. 48-55. *Journal of the peripheral nervous system* (IF 1.49)
64. Merkies, I. S. J., Sobue, G, Durn, B., Shebl, A., van Schaik, I. N., **Path Study Group**, Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. *J Peripher Nerv Syst*, 2019. 24(1):p.72-79. (IF 1.49)
65. Métral M, Nadin I, Locatelli I, Tarr PE, Calmy A, Kovari H, Brugger P, Cusini A, Gutbrod K, Schmid P, Schwind M, Kunze U, Di Benedetto C, Pignatti R, Du Pasquier R, Darling K, Cavassini M; How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? Neurocognitive Assessment in the Metabolic and Aging Cohort (**NAMACO**) study group (incl. **Derfuss T.**) Swiss HIV Cohort Study. *HIV Med*. 2019 Dec 27. (IF 3.734)
66. Métral M, Darling K, Locatelli I, Nadin I, Santos G, Brugger P, Kovari H, Cusini A, Gutbrod K, Tarr PE, Calmy A, Lecompte TD, Assal F, Monsch A, Kunze U, Stoeckle M, Schwind M, Schmid P, Pignatti R, Di Benedetto C, Du Pasquier R, Cavassini M; The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile. **NAMACO study group (incl. Derfuss T.)**; Swiss HIV Cohort Study. *HIV Med*. 2020 Jan;21(1):30-42. doi: 10.1111/hiv.12795. Epub 2019 Oct 7 (IF 3.734)
67. Metzger K, Gamp M, Tondorf T, Hochstrasser S, Becker C, Luescher T, Rasiah R, Boerlin A, Tisljar K, Emsden C, **Sutter R**, Schaefer R, Meinlschmidt G, Marsch S, Hunziker S. Depression and anxiety in relatives of out-of-hospital cardiac arrest patients: Results of a prospective observational study. *J Crit Care*. 2019; 51: 57-63. (IF 2.783)

68. Miller AE, Vermersch P, **Kappos L**, Comi G, Freedman MS, Oh J, De Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; Topic Study Group. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. *Mult Scler Relat Disord*. 2019 May 24;33:131-138 (IF 2.725)
69. Muller MD, Gregson J, McCabe DJH, Nederkoorn PJ, Van Der Worp HB, De Borst GJ, Cleveland T, Wolff T, **Engelter ST**, **Lyrer PA**, Brown MM and **Bonati LH**. Stent Design, Restenosis and Recurrent Stroke After Carotid Artery Stenting in the International Carotid Stenting Study. *Stroke*. 2019;50:3013-20. (IF 6.046)
70. **Naegelin Y**, Naegelin P, von Felten S, **Lorscheider L**, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, **Kappos L**, **Derfuss T**. Rituximab Treatment in Secondary Progressive Multiple Sclerosis is associated with reduced Disability Progression. *JAMA Neurol* 2019 Mar 1;76(3):274-281. (IF 12.321)
71. **Nagy S**, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. *Trials*. 2019 Nov 21;20(1):637. (IF 1.975)
72. **Nagy S**, Schädelin S, Hafner P, **Bonati U**, Scherrer D, Ebi S, Schmidt S, **Orsini AL**, Bieri O, Fischer D. Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy. *Muscle Nerve*. 2020 Jan;61(1):63-68. (IF 2.393)
73. **Nagy S**, Schmidt S, Hafner P, Klein A, Rubino-Nacht D, Gocheva V, Bieri O, Vuillerot C, **Bonati U**, Fischer D. Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy. *J Vis Exp*. 2019 Jan 12;(143). (IF 0.879)
74. Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, Balk L, Brandt AU, Martínez-Lapiscina EH, Saidha S, Villoslada P, Al-Hassan AA, Behbehani R, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, **Papadopoulou A**, Pisa M, Zimmermann H, Galetta SL, Balcer LJ; International Multiple Sclerosis Visual System Consortium. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. *Ann Neurol* 2019;85:618-629. (IF 9.496)
75. **Papadopoulou A**, Oertel FC, **Gaetano L**, Kuchling J, Zimmermann H, Chien C, Siebert N, Asseyer S, Bellmann-Strobl J, Ruprecht K, Chakravarty MM, Scheel M, **Magon S**, **Wuerfel J**, Paul F, Brandt AU. Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. *J Neurol Neurosurg Psychiatry* 2019;90: 1156-1164. (IF 8.272)
76. **Papadopoulou A**, **Gaetano L**, **Pfister A**, **Altermatt A**, **Tsagkas C**, Morency F, Brandt AU, **Hardmeier M**, Chakravarty MM, Descoteaux M, **Kappos L**, **Sprenger T**, **Magon S**. Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway. *Neurology* 2019;92(19):e2240-e2249. (IF 8.689)

77. Pasquier B, Borisow N, Rasche L, Bellmann-Strobl J, Ruprecht K, Niendorf T, **Derfuss TJ, Wuerfel J**, Paul F, **Sinnecker T**. Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. *Neurol Neuroimmunol Neuroinflamm.* 2019 Mar 7;6(3):e541. (IF 7.353)
78. Pfuhl, C., Grittner, U., Giess, R. M., Scheel, M., Behrens, J. R., Rasche, L., Pache, F. C., Wenzel, R., Brandt, A. U., Bellmann-Strobl, J, Paul, F., Ruprecht, K., **Oechtering, J.**, Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. *Neurology*, 2019. 93(15): p. e1439-e1451. (IF 8.689)
79. Pinter D, Gattringer T, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, **Barro C**, Eppinger S, Pirpamer L, Bachmaier G, Ropele S, Wardlaw JM, **Kuhle J**, Khalil M, Fazekas F. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. *J Cereb Blood Flow Metab* 2019, 39:1669-1677 (IF 6.045)
80. Piredda G., Hilbert T., **Granziera C.**, Meuli R., Molinari F., Thiran J.P., Kober T. Quantitative brain relaxation atlases for personalized detection of brain pathology. *Magnetic Resonance Imaging in Medicine (MRM)*, *Magn Reson Med.* 2020 Jan;83(1):337-351. Epub 2019 Aug 16. (IF 3.858)
81. **Polymeris AA**, Curtze S, Erdur H, Hametner C, Heldner MR, Groot AE, Zini A, Bejot Y, Dietrich A, Martinez-Majander N, Von Rennenberg R, Gumbinger C, Schaedelin S, **De Marchis GM, Thilemann S, Traenka C, Lyrer PA, Bonati LH**, Wegener S, Ringleb PA, Tatlisumak T, Nolte Ch, Scheitz JF, Arnold M, Strbian D, Nederkoorn PJ, **Gensicke H, Engelter ST** and Collaborators T Intravenous thrombolysis for suspected ischemic stroke with seizure at onset *Ann Neurol* 2019;86:770-79. (IF 9.496)
82. Preische O*, Schultz S*, Apel A*, **Kuhle J**, Kaeser SA, **Barro C**, Gräber-Sultan S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M. *Equal contribution. Within-person rate of change in blood neurofilament light chain predicts neurodegeneration and disease progression in presymptomatic Alzheimer's disease. *Nature Medicine* 2019, 25:277-283, 2019. (IF 32.621)
83. **Pröbstel AK**, Thanei M, Erni B, **Lecourt AC**, Branco L, André R, Roux-Lombard P, Koenig KF, Huynh-Do U, Ribí C, Chizzolini C, **Kappos L**, Trendelenburg M, **Derfuss T**. Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2019 May 1;58(5):908-913. (IF 5.149)
84. Rojas OL*, **Pröbstel AK***, Porfilio P*, Wang A, Charabati M, Sun T, Lee D, Galicia G, Ramaglia V, Ward LA, Leung LYT, Najafi G, Khalegi K, Chiaranunt P, Garcillan B, Li A, Besla R, Naouar I, Cao EY, Yam J, Luck H, Campbell DJ, Allman D, Brooks DG, Tomura M, Baumann R, Zamvil SS, Bar-Or A, Horwitz MS, Winer DA, Mortha A, Mackay F, Prat A, Osborne L, Robbins C, Baranzini SE, Gommerman JL. Recirculating Intestinal IgA-producing cells Regulate

Neuroinflammation via IL10. *Cell*. 2019; 176(3):610-624. *Equal contribution (IF 31.4)

85. **Ruberte E, Sinnecker T, Amann M, Gaetano L, Naegelin Y, Penner IK, Kuhle J, Derfuss T, Kappos L., Granziera C, Wuerfel J, Yaldizli Ö.** Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis *Eur Neurol*. 2019 Jan 3;80(3-4):207-214. (IF 4.387)
86. Rybitschka A, Semmlack S, Kaplan P, **DeMarchis GM, Rüegg S, Marsch S, Sutter R.** Calorie intake during status epilepticus and outcome: A 5-year cohort study. *Crit Care Med* 2019; 47(8): 1106-1115. (IF 6.971)
87. Saller T, Petzold A, Zetterberg H, **Kuhle J**, Chappell D, von Dossow V, Klawitter F, Schurholz T, Hagl C, Reuter DA, Zwissler B, Ehler J. A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2019 Sep;163(3):241-246 (IF 1.141)
88. **Sander L, Pezold S, Andermatt S, Amann M, Meier D, Wendebourg MJ, Sinnecker T, Radue EW, Naegelin Y, Granziera C, Kappos L, Wuerfel J, Cattin P, Schlaeger R;** Alzheimer's Disease Neuroimaging Initiative. Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases. *Hum Brain Mapp*. 2019 Oct 1;40(14):4091-4104. (IF 4.554)
89. Schmid P, Pignatti R, Di Benedetto C, Du Pasquier R, Cavassini M; NAMACO study group (including **Derfuss T**); Swiss HIV Cohort Study. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile. *HIV Med*. 2020 Jan;21(1):30-42. Epub 2019 Oct 7. (IF 3.7)
90. **Seiffge DI, Paciaroni M, Wilson D, Koga M, Macha K, Cappellari M, Schaedelin S, Shakeshaft C, Takagi M, Tsivgoulis G, Bonetti B, Kallmunzer B, Arihiro S, Alberti A, Polymeris AA, Ambler G, Yoshimura S, Venti M, Bonati LH, Muir Kw, Yamagami H, Thilemann S, Altavilla R, Peters N, Inoue M, Bobinger T, Agnelli G, Brown MM, Sato S, Acciarresi M, Jager Hr, Bovi P, Schwab S, Lyrer P, Caso V, Toyoda K, Werring Dj, Engelter ST, De Marchis GM, Cromis Rafrafdsnle And Verona Registry C** Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation *Ann Neurol* 2019;85:823-34. (IF 9.496)
91. Semmlack S, Kaplan PW, Spiegel R, **DeMarchis GM, Hunziker S, Tisljar K, Rüegg S, Marsch S, Sutter R.** Illness severity scoring in status epilepticus – When STESS meets APACHE II, SAPS II, and SOFA. *Epilepsia* 2019; 60(2): 189-200. (IF 5.562)
92. Siller N, **Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.** Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. *Mult Scler J*, 25:678-686, 2019. (IF 5.649)

93. **Sinnecker T, Ruberte E**, Schädelin S, Canova V, **Amann M, Naegelin Y**, Penner IK, **Müller J, Kuhle J, Décard B, Derfuss T, Kappos L, Granziera C, Wuerfel J, Magon S, Yaldizli Ö**. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. *J Neurol* 2020; 267(1):192-202. (IF 4.204)
94. **Sinnecker T**, Andelova M, Mayr M, **Rüegg S, Sinnreich M**, Hench J, Frank S, Schaller A, Stippich C, **Wuerfel J, Bonati LH**. Diagnosis of adult-onset MELAS syndrome in a 63-year-old patient with suspected recurrent strokes - a case report. *BMC Neurol* 2019; 19(1):91. Similar articles (IF 2.1)
95. **Sinnecker T**, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, **Kappos L**, Montalban X, Rovira À, Evangelou N, **Wuerfel J**; MAGNIMS Study Group. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. *JAMA Neurol* 2019. doi: 10.1001/jamaneurol.2019.2478. [Epub ahead of print]. (IF 12.321)
96. **Sinnecker T**, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. *BMC Neurol* 2019; 19(1):190. (IF 2.233)
97. **Sinnecker T, Wuerfel J**. Untangling normal aging from disease-related brain atrophy in MS. *Neurol Neuroimmunol Neuroinflamm* 2019; 6(6). (IF 7.353)
98. Skachokova Z, Martinisi A, Flach M, Sprenger F, **Naegelin Y**, Steiner-Monard V, **Sollberger M**, Monsch AU, Goedert M, Tolnay M, Winkler DT. Cerebrospinal fluid from Alzheimer's disease patients promotes tau aggregation in transgenic mice. *Acta Neuropathologica Communications* 2019; 7:72. (IF 5.883)
99. Sormani MP, Destefano N, Giovannoni G, Langdon D, Piani Meier D, Haering DA, **Kappos L**, Tomic D. Learning ability correlates with brain atrophy and disability progression in RRMS *J Neurol Neurosurg Psychiatry*. 2019 Jan;90(1):38-43 (IF 8.327)
100. Sormani MP, Haering DA, Kropshofer H, **Leppert D, Barro C, Kappos L**, Tomic DVM*, **Kuhle J***. *Equal contribution. Blood neurofilament light as a potential endpoint in Phase 2 studies in multiple sclerosis. *Annal Clin Transl Neurol*, 6:1081-1089, eCollection 2019 Jun. (IF 4.656)
101. Spirgi S, **Meyer A, Calabrese P, Gschwandtner U, Fuhr P**. Effects of Cognitive Performance and Affective Status on Fatigue in Parkinson's Disease. *Dement Geriatr Cogn Disord Extra* 2019;9:344–351 (IF 0.95)
102. **Sprenger T, Kappos L, Radue EW, Gaetano L, Mueller-Lenke N, Wuerfel J**, Poole EM, Cavalier S. Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide. *Mult Scler*. 2019 June 1-10, (IF: 5.649)

103. Streckmann F, Hess V, Bloch W, **Décard BF**, Ritzmann R, Lehmann HC, Balke M, Koliamitra C, Oschwald V, Elter T, Zahner L, Donath L, Roth R, Faude O. Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH. *BMJ Open*. 2019 Apr 24;9(4):e024467. doi: 10.1136/bmjopen-2018-024467. (IF 2.376)
104. **Sutter R**, Semmlack S, Opic P, Spiegel R, **DeMarchis GM**, Hunziker S, Kaplan PW, **Rüegg S**, Marsch S. Untangling operational failures of the Status Epilepticus Severity Score (STESS). *Neurology* 2019; 92(17): e1948-1956. (IF 8.689)
105. **Sutter R**, Semmlack S, Kaplan PW, Opic P, Marsch S, **Rüegg S**. Prolonged status epilepticus: Early recognition and prediction of full recovery in a 12-year cohort. *Epilepsia* 2019; 60(1): 42-52. (IF 5.562)
106. **Sutter R**, Tisljar K, Opić P, **De Marchis GM**, Bassetti S, Bingisser R, Hunziker S, Marsch S. Emergency management of status epilepticus in a high-fidelity simulation: a prospective study. *Neurology*. 2019; 93(19): 838-848. (IF 8.689)
107. **Tsagkas C**, Horvath A, **Altermatt A**, Pezold S, Weigel M, Haas T, **Amann M**, **Kappos L**, **Sprenger T**, Bieri O, Cattin P, **Parmar K**. Automatic Spinal Cord Gray Matter Quantification: A Novel Approach. *AJNR Am J Neuroradiol*. 2019 Sep;40(9):1592-1600. doi: 10.3174/ajnr.A6157. Epub 2019 Aug 22. (IF 3.256)
108. Turner B, Cree B, **Kappos L**, Montalban X, Papeix C, Wolinsky J, Buffels R, Fiore D, Garren H, Han J, Hauser S. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. *J Neurol*. 2019 Feb 28.1–12 (IF 4.387)
109. Van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, **Michalak Z**, **Barro C**, van Schaik IN, **Kuhle J**, Eftimov F. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. *J Peripher Nerv Syst*, 24:187-194, 2019. (IF 2.441)
110. Van Munster CE, **D'Souza M**, Steinheimer S, Kamm CP, Burggraaff J, **Diederich M**, **Kravalis K**, Dorn J, Walsh L, Dahlke F, **Kappos L**, Uitdehaag BM. Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis. *Mult Scler*. 2019 Oct;25(12):1673-1681 (IF 5.649)
111. Watanabe M, Nakamura Y, **Michalak Z**, Isobe N, **Barro C**, **Leppert D**, MD2, Matsushita T, Hayashi F, Yamasaki R, **Kuhle J***, Kira J*. *Equal contribution. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. *Neurology*, 93:e1299-e1311, 2019. (IF 8.689)
112. **Wendebourg MJ***, **Nagy S***, **Derfuss T**, **Parmar K**, **Schlaeger R**. Magnetic resonance imaging in immune-mediated myelopathies. *equally contributed *J Neurol*. 2019 Jan 29. doi: 10.1007/s00415-019-09206-2. [Epub ahead of print] Review. (IF 4.2)

113. Wilke C, Pujol F, **Barro C**, Stransky E, Blennow K, **Michalak Z**, Deuschle C, Jeromin A, Zetterberg H, Schüle R, Höglund K*, **Kuhle J***, Synofzik M*. *Equal contribution. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. *Clin Chem Lab Med*, 57:1556-1564, 2019. (IF 3.556)
114. Wilson D, Ambler G, Lee KJ, Lim JS, Shiozawa M, Koga M, Li L, Lovelock C, Chabriat H, Hennerici M, Wong YK, Mak HKF, Prats-Sanchez L, Martinez-Domene A, Inamura S, Yoshifuji K, Arsava EM, Horstmann S, Purrucker J, Lam Byk, Wong A, Kim YD, Song TJ, Schrooten M, Lemmens R, Eppinger S, Gattringer T, Uysal E, Tanriverdi Z, Bornstein NM, Assayag EB, Hallevi H, Tanaka J, Hara H, Coutts SB, **Hert L**, **Polymeris A**, **Seiffge DJ**, **Lyrer P**, Algra A, Kappelle J, Al-Shahi Salman R, Jager HR, Lip GYH, Mattle HP, Panos LD, Mas JI, Legrand L, Karayiannis C, Phan T, Gunkel S, Christ N, Abrigo J, Leung T, Chu W, Chappell F, Makin S, Hayden D, Williams DJ, Kooi ME, Van Dam-Nolen DHK, Barbato C, Browning S, Wiegertjes K, Tuladhar AM, Maaijwee N, Guevarra C, Yatawara C, Mendyk AM, Delmaire C, Kohler S, Van Oostenbrugge R, Zhou Y, Xu C, Hilal S, Gyanwali B, Chen C, Lou M, Staals J, Bordet R, Kandiah N, De Leeuw FE, Simister R, Van Der Lugt A, Kelly PJ, Wardlaw JM, Soo Y, Fluri F, Srikanth V, Calvet D, Jung S, Kwa VIH, **Engelter ST**, **Peters N**, Smith EE, Yakushiji Y, Orken DN, Fazekas F, Thijs V, Heo JH, Mok V, Veltkamp R, Ay H, Imaizumi T, Gomez-Anson B, Lau KK, Jouvent E, Rothwell PM, Toyoda K, Bae HJ, Marti-Fabregas J, Werring DJ and Microbleeds International Collaborative N. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. *Lancet Neurol*. 2019;18:653-65. (IF 28.755)
115. Wong YYM, Bruijstens AL, **Barro C**, **Michalak Z**, Melief MJ, Wierenga AF, van Pelt ED, Neuteboom RF, **Kuhle J***, Hintzen RQ*. * Equal contribution. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. *Neurology* 2019, 93:e968-e974 (IF 8.689)
116. Zelano J...(+36 collaborators of the ESBACE consortium collaborators)... **Rüegg S**....The provision of epilepsy care across Europe 2017: A 17-year follow-up survey. *Epilepsia Open* 2019; 4(1): 144-152. (IF n/a)
117. **Zimmermann M**, **Rose N**, Lindner JM, Kim H, Gonçalves AR, Callegari I, Syedbasha M, Kaufmann L, Egli A, **Lindberg RLP**, **Kappos L**, Traggiati E, **Sanderson NSR**, **Derfuss T**. Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells. *Front Immunol*. 2019 Apr 16;10:829. (IF 4.716)

Reviews, Editorials:

1. Arnold P, Bonetti C, Mathis J, Meyer K, Seeck M, Seeger R, Wiest D, **Rüegg S**, Krämer G, Franke J. Fahrreignung mit Epilepsie. *Swiss Med Forum* 2019; 19(45-46): 737-740. (IF n/a)).
2. Bridel C, van Wieringen WN, Alvarez-Cermeño J, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen, Fialova L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, **Kappos L**, Khademi M, Khalil M, **Kuhle J**, Landén M, Leinonen V, Logroscino G, Lu C, Lycke J, Magdalinaou NA, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T11, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö O, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillback T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vårgberg M, Verbeek M20, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelso C, Wild EJ, Zetterberg H, Tijms BM, Teunissen CE. Diagnostic value of cerebrospinal fluid neurofilament light protein in Neurology: a systematic review and individual participant meta-analysis. *JAMA Neurol*, ahead of print, 2019. (IF 12.321)
3. Doerig P, **Rueegg S**, Welge-Lüssen A. Reversible unilateral anosmia postictally in a patient with forntotemporal lobe epilepsy. *Chemical Senses* 2019; 44(7): E46-E47. (IF 2.336)
4. Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Bricchetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Broła W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, **Kuhle J**, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orogas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seelldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C. Multiple sclerosis registries in Europe - An updated mapping survey. *Mult Scler Relat Disord*, 27:171-178, 2019. (IF 2.725)
5. Grzonka P, Tisljar K, **Rüegg S**, Marsch S, **Sutter R**. What to exclude when brain death is suspected. *J Crit Care*. 2019; 53: 212-217. (IF 2.783)
6. Grzonka P, Rybitschka A, **De Marchis GM**, Marsch S, **Sutter R**. Bone fractures from generalized convulsive status epilepticus – a systematic review. *Epilepsia*. 2019; 60(5): 996-1004. (IF 5.562)
7. Jokubaitis VG, **Pröbstel AK**, Arrambide G, Costello F, Waubant E. Introducing the International Women in Multiple Sclerosis network. *Lancet Neurology*. 2019; 18(6):521. PMID: 31122489 (IF 28.755)
8. Lanz TV, **Pröbstel AK**, Mildenerberger I, Platten M, Schirmer L. Single-cell high-throughput technologies in cerebrospinal fluid research and diagnostics. *Frontiers Immunology*. 2019; 10:1302. (IF 4.716)

9. **Leppert D, Kuhle J.** Blood neurofilament light chain at the doorstep of clinical application. *Neurol Neuroimmunol Neuroinflamm.* 2019 Aug 8;6(5):e599 (IF 7.353)
10. **Leppert D, Kuhle J.** Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes. *Mult Scler.* 2020 Jan;26(1):17-19. Epub 2019 Oct 18 (IF 5.649)
11. **Pröbstel AK, Zamvil SS.** Do maternal anti-NMDAR antibodies promote development of neuropsychiatric disease in children? *Annals of Neurology.* 2019; 86(5):653-655. PMID:31531881 (IF 9.496)
12. **Rüegg S, Yeh EA, Honorat J.** Forecasting outcomes in anti-NMDAR encephalitis: Clearer prognostic markers needed.(Editorial). *Neurology* 2019; 92(3): 119-120. (IF 8.689)
13. **Rüegg S.** The new classification of epilepsy and seizures of the International League Against Epilepsy. (Minireview). *Swiss Arch Neurol Psychiatr Psychother* 2019; 170(5): w03059. (IF: n/a).
14. Sabatino JJ*, **Pröbstel AK***, Zamvil SS. B cells in CNS Autoimmune and Neurodegenerative Disorders. *Nature Reviews Neuroscience* 2019; 20(12):728-745 (IF 32.635)
15. Schmitt FC, Haberland DE, **Rüegg S.** Über den gemeinsamen Nenner von Cannabinoiden, Quellenlokalisierung, Schlaganfall, sozialer Kognition und Status epilepticus. (Editorial). *Zeitschr Epileptol* 2019; 32(3): 173-174. (IF: n/a).
16. **Sinnecker T, Andelova M, Mayr M, Rüegg S, Sinnreich M, Hench J, Frank S, Schaller A, Stippich C, Würfel J, Bonati LH.** Diagnosis of adult-onset MELAS-syndrome in a 63-year-old patient with suspected recurrent strokes – a case report. *BMC Neurol* 2019; May 8;19(1):91. doi: 10.1186/s12883-019-1306-6. (IF 2.233)
17. Tyler KL, **Rüegg S.** The neuromythology of Hashimoto encephalopathy: The emperor has no clothes. (Editorial). *Neurology* 2019; Dec 27. pii:10.1212/WNL.0000000000008776. doi: 0.1212/WNL.0000000000008776. [Epub ahead of print]. (IF 8.689)